Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juanbi Granule is a Traditional Chinese Medicine (TCM) hospital preparation developed by the Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine). It is specifically formulated for the treatment of rheumatoid arthritis (RA) and other "Bi syndromes" (painful obstruction syndromes) in TCM. The preparation is designed to dispel wind, eliminate dampness, and unblock the collaterals to alleviate joint pain, swelling, and morning stiffness. Pharmacological studies indicate that Juanbi Granule possesses significant anti-inflammatory and immunomodulatory properties, working by suppressing the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), and inhibiting the NF-κB signaling pathway. It is a widely used clinical preparation in Yunnan province for chronic inflammatory joint diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Juanbi Granule.